# US 2025/0164510 A1 · Use of gamma prime fibrinogen as a biomarker in the assessment of covid-19 infections and prognosis of severe disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0164510 A1
- Document ID: US20250164510A1
- Status: Published application
- Kind: A1
- Application number: 18/841,731
- Filed: 2022-07-05
- Published: 2025-05-22
- Earliest claimed: 2022-02-27
- Assignees: Gamma Diagnostics Inc.
- Applicants: Gamma Diagnostics Inc.
- Inventors: Cn RAMCHAND; David H. FARRELL; Steven C. KAZMIERCZAK; William MESSER; Akram KHAN; Ajay Sasikumar NAIR
- Web page: https://patentgrep.com/patent/US20250164510A1

## CPC

- A61P 31/14: for RNA viruses
- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- C12Q 1/56: involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
- G01N 33/56983: {Viruses}
- G01N 33/6869: {Interleukin}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 2333/4737: C-reactive protein
- G01N 2333/5412: IL-6
- G01N 2333/75: Fibrin; Fibrinogen
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A method of assessing a COVID-19 infection in a person, the method comprising analysing the concentration or levels of one or more biomarkers in a biological sample from a person, wherein the one or more biomarkers comprises γ′ fibrinogen, and wherein concentration or levels of γ′ fibrinogen are elevated in a biological sample from a person infected with COVID-19 and can be used for predicting COVID-19 disease severity and/or for making a prognosis of severe COVID-19 disease in a person infected with COVID-19.

## Claims

### Claim 1

A method of assessing a COVID-19 infection in a person, the method comprising analysing the concentration or levels of one or more biomarkers in a biological sample from a person, wherein the one or more biomarkers comprises γ′ fibrinogen.

### Claim 2 (depends on 1)

A method according to claim 1, wherein analysing the concentration or levels of one or more biomarkers in a biological sample from a person, wherein the one or more biomarkers comprises γ′ fibrinogen, comprises detecting and quantifying the amount of the one or more biomarkers in a blood sample from the person.

### Claim 3 (depends on 1)

A method according to claim 1, wherein concentration or levels of γ′ fibrinogen in a biological sample from a person infected with COVID-19 are elevated when compared to a biological sample taken from the person when the person was not infected with COVID-19 or when compared to biological samples taken from one or more other persons not infected with COVID-19.

### Claim 4 (depends on 1)

A method according to claim 1, wherein concentration or levels of γ′ fibrinogen is greater than approximately 46 mg/dl in a biological sample from a person infected with COVID-19.

### Claim 5 (depends on 1)

A method according to claim 1, wherein analysing the concentration or levels of one or more biomarkers in a biological sample from a person, wherein the one or more biomarkers comprises γ′ fibrinogen, is used for predicting COVID-19 disease severity and/or for making a prognosis of severe COVID-19 disease in a person infected with COVID-19.

### Claim 6 (depends on 5)

A method according to claim 5, wherein a concentration of γ′ fibrinogen of between approximately 46 mg/dL and 67 mg/dl in a biological sample from a person indicates a mild to moderate COVID-19 infection in the person.

### Claim 7 (depends on 5)

A method according to claim 5, wherein a concentration of γ′ fibrinogen of approximately 67 mg/dL or greater in a biological sample from a person indicates a severe COVID-19 infection in the person.

### Claim 8 (depends on 6)

A method according to claim 6, wherein a concentration of γ′ fibrinogen of between approximately 46 mg/dL and 67 mg/dl in the biological sample from the person indicates a mild to moderate COVID-19 infection in the person corresponding to a SpO2 of above approximately 91% in the person.

### Claim 9 (depends on 7)

A method according to claim 7, wherein a concentration of γ′ fibrinogen of approximately 67 mg/dL or greater in the biological sample from the person indicates a severe COVID-19 infection in the person corresponding to a SpO2 of below approximately 91% in the person.

### Claim 10 (depends on 1)

A method according to claim 1, wherein an assay is used in analysing the concentration or levels of the one or more biomarkers in a biological sample from a person, wherein the one or more biomarkers comprises γ′ fibrinogen.

### Claim 11 (depends on 10)

A method according to claim 10, wherein the assay comprises an ELISA.

### Claim 12 (depends on 1)

A method according to claim 1, wherein the one or more biomarkers further comprise D-Dimer and/or ferritin.

### Claim 13 (depends on 1)

A method according to claim 1, wherein the one or more biomarkers further comprise CRP and/or IL-6.

### Claim 14 (depends on 5)

A method according to claim 5, wherein COVID-19 disease severity or severe COVID-19 disease comprises ICU admission and/or ventilation for the COVID-19 infected person.

### Claim 15 (depends on 5)

A method according to claim 5, wherein COVID-19 disease severity or severe COVID-19 disease comprises a SpO2 of below approximately 91% in the COVID-19 infected person.

### Claim 16 (depends on 1)

A method of treating a person infected with COVID-19 according to the severity of their COVID-19 infection as determined using a method of assessing a COVID-19 infection in a person according to claim 1.

### Claim 17 (depends on 1)

A method for prognosis of COVID-19 disease severity in a person comprising a method of assessing a COVID-19 infection in a person according to claim 1.

### Claim 18 (depends on 10)

A kit for diagnosing, monitoring, and/or forming a prognosis of disease severity of COVID-19 in a person comprising an assay according to claim 10.

### Claim at position 19

19-32. (canceled)
